13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001977548
Total reported value
$389.8M
$389.8M
8 檔
70.3%
During the Q1 2026 filing period, Checkpoint Capital L.P. (CIK: 0001977548) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $389.8M across 8 reported positions.
In Q1 2026, Checkpoint Capital L.P. displayed an active expansion posture, initiating 3 new positions and adding to 3 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ARGX | Argenx Se - Adr | Stock-Healthcare | 40.10% | -8.85% | +7.75% | |
| 2 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 38.30% | -4.51% | +23.68% | |
| 3 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 9.16% | +10.56% | -29.04% | |
| 4 | IRON | Disc Medicine Inc | Stock-Other | 6.58% | -2.07% | -36.72% | |
| 5 | CYTK | Cytokinetics Inc | Stock-Healthcare | 4.26% | +6.12% | +7.90% | |
| 6 | SEPN | Septerna Inc | Stock-Other | 0.86% | -0.86% | EXIT | |
| 7 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.52% | -0.52% | EXIT | |
| 8 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.21% | +0.15% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RYTM | Rhythm Pharmaceuticals Inc | +5.1% | +23.68% | Add |
| 2 | ARGX | Argenx Se - Adr | +2.8% | +7.75% | Add |
| 3 | CYTK | Cytokinetics Inc | +1% | +7.90% | Add |
| 4 | RVMD | Revolution Medicines Inc | -0.1% | -29.04% | Trim |
| 5 | IRON | Disc Medicine Inc | -4.7% | -36.72% | Trim |
| 6 | CORT | Corcept Therapeutics Inc | — | EXIT | Sold out |
| 7 | SEPN | Septerna Inc | — | NEW | New buy |
| 8 | CRNX | Crinetics Pharmaceuticals In | — | NEW | New buy |
| 9 | TRVI | Trevi Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Checkpoint Capital L.P. reported a total U.S. public equity portfolio value of $389.8M across 8 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ARGX, RYTM, RVMD) accounted for 70.3% of total reported equity market value during Q1 2026.
Top New Position Initiated
SEPN
市值: $2.4M
Top Position Liquidated / Trimmed
CORT
前期市值: $18.4M
During Q1 2026, Checkpoint Capital L.P.'s top holdings by market value included ARGX (40.1%)、RYTM (38.3%)、RVMD (9.2%). The largest single position, ARGX, represented 40.1% of total portfolio value.
In Q1 2026, Checkpoint Capital L.P. made 9 total portfolio adjustments, initiating 3 new buys, adding to 3 positions, trimming 2 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.